Anavex Life Sciences (AVXL) 10-K 16 Dec 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2019	Dec. 12, 2019	Mar. 31, 2019
Document And Entity Information
Entity Registrant Name	ANAVEX LIFE SCIENCES CORP.
Entity Central Index Key	0001314052
Document Type	10-K
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity Shell Company	false
Entity's Reporting Status Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	NV
Entity File Number	001-37606
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 139,768,112
Entity Common Stock, Shares Outstanding		56,123,076
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Current
Cash and cash equivalents	$ 22,185,630	$ 22,930,638
Incentive and tax receivables	2,642,745	1,870,357
Prepaid expenses and deposits	500,998	1,251,798
Total Current Assets	25,329,373	26,052,793
Deferred costs		101,133
Deposits		52,396
Total Assets	25,329,373	26,206,322
Current Liabilities
Accounts payable	3,523,332	2,955,293
Accrued liabilities	1,516,342	929,333
Total Liabilities	5,039,674	3,884,626
Capital stock
Authorized: 10,000,000 preferred stock, par value $0.001 per share
Authorized: 100,000,000 common stock, par value $0.001 per share, Issued and outstanding: 52,650,251 common shares (2018 - 45,933,472)	52,652	45,935
Additional paid-in capital	153,633,807	129,377,542
Accumulated deficit	(133,396,760)	(107,101,781)
Total Stockholders' Equity	20,289,699	22,321,696
Total Liabilities and Stockholders' Equity	$ 25,329,373	$ 26,206,322

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Sep. 30, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	10,000,000	10,000,000
Capital shares, par value (in dollars per share)	$ 0.001	$ 0.001
Capital shares, authorized	100,000,000	100,000,000
Capital shares, issued	52,650,251	45,933,472
Capital shares, outstanding	52,650,251	45,933,472

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating expenses
General and administrative	$ 6,846,599	$ 5,989,170
Research and development	22,260,349	13,344,421
Total operating expenses	(29,106,948)	(19,333,591)
Other income (expenses)
Grant income	298,943	149,055
Research and development incentive income	2,465,691	1,830,186
Interest income, net	207,280	255,092
Gain on settlement of accounts payable	115,758
Financing related charges	(151,133)	(30,943)
Foreign exchange gain (loss), net	(42,389)	(49,789)
Total other income, net	2,894,150	2,153,601
Net loss before provision for income taxes	(26,212,798)	(17,179,990)
Income tax expense, current	(82,181)	(72,746)
Net loss and comprehensive loss	$ (26,294,979)	$ (17,252,736)
Net Loss per share Basic and diluted (in dollars per share)	$ (0.54)	$ (0.39)
Weighted average number of shares outstanding Basic and diluted (in shares)	48,906,470	44,655,725

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows used in Operating Activities
Net loss	$ (26,294,979)	$ (17,252,736)
Adjustments to reconcile net loss to net cash used in operations:
Stock-based compensation	6,430,873	5,517,004
Deferred costs	151,133
Gain on settlement of accounts payable	(115,758)
Changes in non-cash working capital balances related to operations:
Incentive and tax receivables	(772,388)	(231,096)
Prepaid expenses and deposits	803,196	(915,870)
Accounts payable	683,797	38,233
Accrued liabilities	587,009	262,059
Net cash used in operating activities	(18,527,117)	(12,582,406)
Cash Flows provided by Financing Activities
Issuance of common shares	17,832,109	8,173,920
Deferred financing charges	(50,000)	(101,133)
Net cash provided by financing activities	17,782,109	8,072,787
Decrease in cash and cash equivalents during the period	(745,008)	(4,509,619)
Cash and cash equivalents, beginning of year	22,930,638	27,440,257
Cash and cash equivalents, end of year	$ 22,185,630	$ 22,930,638

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance Beginning at Sep. 30, 2017	$ 43,332	$ 115,689,221	$ (89,849,045)	$ 25,883,508
Balance Beginning (in shares) at Sep. 30, 2017	43,330,817
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under purchase agreement - purchase shares	$ 2,384	8,171,536		8,173,920
Shares issued under purchase agreement - purchase shares (in shares)	2,383,580
Shares issued under purchase agreement - commitment shares	$ 15	(15)
Shares issued under purchase agreement - commitment shares (in shares)	14,681
Shares issued pursuant to cashless exercise of options	$ 78	(78)
Shares issued pursuant to cashless exercise of options (in shares)	78,646
Shares issued pursuant to cashless exercise of warrants	$ 126	(126)
Shares issued pursuant to cashless exercise of warrants (in shares)	125,748
Share based compensation		5,517,004		5,517,004
Net loss			(17,252,736)	(17,252,736)
Balance Ending at Sep. 30, 2018	$ 45,935	129,377,542	(107,101,781)	$ 22,321,696
Balance Ending (in shares) at Sep. 30, 2018	45,933,472			45,933,472
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued under purchase agreement - purchase shares	$ 4,849	13,192,755		$ 13,197,604
Shares issued under purchase agreement - purchase shares (in shares)	4,848,995
Shares issued under purchase agreement - commitment shares	$ 24	(24)
Shares issued under purchase agreement - commitment shares (in shares)	23,701
Shares issued under purchase agreement - purchase shares	$ 1,500	4,633,005		4,634,505
Shares issued under purchase agreement - purchase shares (in shares)	1,500,000
Shares issued under purchase agreement - commitment shares	$ 339	(339)
Shares issued under purchase agreement - commitment shares (in shares)	339,415
Shares issued pursuant to cashless exercise of warrants	$ 5	(5)
Shares issued pursuant to cashless exercise of warrants (in shares)	4,938			4,938
Share based compensation		6,430,873		$ 6,430,873
Net loss			(26,294,979)	(26,294,979)
Balance Ending at Sep. 30, 2019	$ 52,652	$ 153,633,807	$ (133,396,760)	$ 20,289,699
Balance Ending (in shares) at Sep. 30, 2019	52,650,521			52,650,251

Business Description and Basis

Business Description and Basis of Presentation	12 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation	Note 1 Business Description and Basis of Presentation Business Anavex Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (“MECP2”). Basis of Presentation These consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Liquidity All of the Company’s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when, if ever, our business might become profitable. The Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will be sufficient to meet its cash commitments for in excess of two years after the date that these consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials. Other than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale down some or all of our research and development activities. Adjustment of Prior Period Financial Statements The Company adjusted amounts to previously reported consolidated financial statements which were immaterial. These adjustments were identified in connection with the preparation of the consolidated financial statements for the year ended September 30, 2019 and related to the timing of recognition of research and development incentive income. Previously the Company accounted for research and development incentive income when received in cash. During the year ended September 30, 2019, based on a continuing assessment regarding the Company’s eligibility for the incentive programs under which it was receiving such income, the Company determined that the income should have been accrued and recorded in the period in which the qualifying research and development expenditures were incurred. The Company evaluated the materiality of these misstatements both qualitatively and quantitatively in accordance with Staff Accounting Bulletin (“SAB”) No. 99 Materiality and SAB No. 108, Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements, and determined that the effect of the adjustment in the period of origination was not material. The Company adjusted the accumulated deficit as of the beginning of the earliest year presented in these consolidated financial statements, resulting in a decrease in the previously reported deficit at October 1, 2017 by $1,629,513 from $(91,478,558) to the adjusted amount $(89,849,045). In addition, the consolidated financial statements for the year ended September 30, 2018 presented herein have been adjusted to include an increase in net income and incentives and taxes receivable as noted below. As Previously Reported Adjustment As Adjusted Balance Sheet: Incentive and tax receivables $ 40,171 $ 1,830,186 $ 1,870,357 Total current assets $ 24,222,607 $ 1,830,186 $ 26,052,793 Total assets $ 24,376,136 $ 1,830,186 $ 26,206,322 Accumulated deficit $ (108,931,967 ) $ 1,830,186 $ (107,101,781 ) Total Stockholders' Equity $ 20,491,510 $ 1,830,186 $ 22,321,696 Total Liabilities and Stockholders' Equity $ 24,376,136 $ 1,830,186 $ 26,206,322 Statement of Operations: Research and development incentive income $ 1,629,513 $ 200,673 $ 1,830,186 Total other income, net $ 1,952,928 $ 200,673 $ 2,153,601 Net loss before provision for income taxes $ (17,380,663 ) $ 200,673 $ (17,179,990 ) Net loss and comprehensive loss $ (17,453,409 ) $ 200,673 $ (17,252,736 ) Statement of Cash Flows: Net loss $ (17,453,409 ) $ 200,673 $ (17,252,736 ) Incentive and tax receivables $ (30,423 ) $ (200,673 ) $ (231,096 ) As the Company adjusted the research and development incentive income for the year ended September 30, 2019 in the Company’s fourth quarter and determined that amounts were immaterial to previously issued unaudited condensed consolidated financial statements, in future filings, the Company will adjust corresponding quarterly amounts included in previously issued unaudited condensed consolidated financial statements for the first, second and third quarter to increase research and development incentive income and reduce net loss by $413,682, $510,990, and $552,335, respectively.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 Summary of Significant Accounting Policies a) Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimate s and the actual results, future results of operations will be affected. b) Principles of Consolidation These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated. c) Cash and equivalents The Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to be cash equivalents. d) Research and Development Expenses Research and development costs are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and stock based compensation expense, contract services including external research and development expenses incurred under arrangements with third parties such as contract research organizations (“CROs”), facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (“ASC”) 730, Research and Development, as these materials have no alternative future use outside of their intended use. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract. In addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability of success and length of time to develop commercial applications of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties, the acquisition of patents and trademarks does not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses. e) Research and Development Incentive Income The Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit (“NYC Biotech credit”), and the Australian research and development tax incentive credit (the “Australia R&D credit”) through a program administered through the Australian Tax Office (the “ATO”), which provides for a cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company’s wholly owned subsidiary, Anavex Australia Pty Ltd. (“Anavex Australia”). The cash refund is available to eligible companies with annual aggregate revenue of less than $20.0 million (Australian) during the reimbursable period. The tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes, since the incentives are not linked to the Company’s taxable income and can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions. With respect to the Australia R&D credit, Anavex Australia may be eligible to receive the cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by the Australian authority pursuant to an advanced overseas finding application. The Company accrues for the amount of cash refund it expects to receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval from the Department of Industry, Innovation and Science in Australia, pursuant to an approved advanced overseas finding application. The Company recognizes the amount of cash refund it expects to receive related to the NYC Biotech credit and Australian research and development tax incentive program when there is reasonable assurance that the cash refund will be received, when the relevant expenditures have been incurred, and when the amount can be reliability measured. This amount is included in Incentive and tax receivables in the accompanying consolidated balance sheets. In addition, Anavex Australia incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an Australian entity, Anavex Australia is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST incurred is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets. f) Basic and Diluted Loss per Share Basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into shares of common stock that were outstanding during the period. As of September 30, 2019, loss per share excludes 8,812,933 (2018 – 7,185,296) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive. g) Financial Instruments The carrying value of the Company’s financial instruments, consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. h) Foreign Currency Translation The functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income in the period in which they occur. The Company has determined that the functional currency of Anavex Australia Pty Limited is the US dollar. The Company has determined that the functional currency of Anavex Germany GmbH is the US dollar. The functional currency of Anavex Canada Ltd. is the Canadian dollar. i) Segment and Geographic Reporting Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment, which is the business of developing novel therapies for the management of CNS diseases. j) Grant Income Research and development incentive income is recognized when the research and development activities have been undertaken and the Company has completed its assessment of whether such activities meet the relevant qualifying criteria. The Company recognizes such income at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research and development costs are incurred. k) Income Taxes The Company has adopted the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes, (“ASC 740”) which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations. l) Stock-based Compensation The Company accounts for all stock-based payments and awards under the fair value method. Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of stock-based payments to non-employees that are fully vested and non-forfeitable at the grant date are measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. The Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital. The Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in these assumptions can materially affect the fair value estimates. m) Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. The book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those instruments. At September 30, 2019 and 2018, the Company did not have any Level 3 assets or liabilities. n) Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard superseded nearly all existing revenue recognition guidance. ASU 2014-09 is effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard did not have a material impact for any period presented. In May 2017, the FASB issued ASU No. 2017-09, “Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting,” clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The new guidance was effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard did not have a material impact for any period presented. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance is effective for the Company beginning on October 1, 2019. The new guidance is required to be applied retrospectively with the cumulative effect recognized at the date of initial application. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows. Other than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Other Income

Other Income	12 Months Ended
	Sep. 30, 2019
Component of Operating Income [Abstract]
Other Income	Note 3 Other Income Grant income During the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant is being received in equal quarterly installments over a period of two years beginning during the year ended September 30, 2018, in exchange for a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome. The grant income is deferred when received and amortized to other income as the related research and development expenditures are incurred. During the year ended September 30, 2019, the Company recognized $298,943 (2018: $149,055) of this grant on its statement of operations as a component of other income. Research and development incentive income Research and development incentive income represents the receipt by the Company’s Australian subsidiary, of the Australian research and development incentive credit, (the “ATO R&D Credit”), as well as receipt by the Company of the New York City Biotechnology Tax Credit (“NYC Biotech credit”). During the year ended September 30, 2019, the Company recorded research and development incentive income of $2,215,691 (AUD 3,281,300) (2018: $1,647,219 (AUD 2,344,486)) in respect of the ATO R&D Credit for eligible research and development expenses incurred during the year. During the year ended September 30, 2019, the Company recorded research and development incentive income of $250,000 (2018: $182,967) in respect of the NYC Biotech Credit awarded to the Company during the year.

Equity Offering Agreements

Equity Offering Agreements	12 Months Ended
	Sep. 30, 2019
Number of shares issued for commitment
Equity Offering Agreements	Note 4 Equity Offering Agreements Controlled Equity Offering Sales Agreement On July 6, 2018, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through Cantor Fitzgerald (the “Offering”). Upon delivery of a placement notice based on the Company’s instructions and subject to the terms and conditions of the Sales Agreement, Cantor Fitzgerald may sell the Shares by methods deemed to be an “at the market offering” offering, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make any sales of Shares under the Sales Agreement. The Company or Cantor Fitzgerald may suspend or terminate the offering of Shares upon notice to the other party, subject to certain conditions. Cantor Fitzgerald will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq. The Company has agreed to pay Cantor Fitzgerald commissions for its services of acting as agent of up to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company also agreed to provide Cantor Fitzgerald with customary indemnification and contribution rights. The Company incurred $151,133 in legal and accounting fees associated with the Sales Agreement. This amount was charged to financing related charges on the statement of operations during the year ended September 30, 2019, based on the passage of time. At September 30, 2019, no shares had been sold pursuant to the Offering. 2015 Purchase Agreement On October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the “2015 Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period. During the year ended September 30, 2019, the Company issued to Lincoln Park an aggregate of 4,872,696 (2018: 2,398,261) shares of common stock under the 2015 Purchase Agreement, including 4,848,995 (2018: 2,383,580) shares of common stock for an aggregate purchase price of $13,197,604 (2018: $8,173,290) and 23,701 (2018: 14,681) as commitment shares. At September 30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement have been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under the 2015 Purchase Agreement. 2019 Purchase Agreement On June 7, 2019, the Company entered into a $50,000,000 purchase agreement (the “2019 Purchase Agreement”) with Lincoln Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time from June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019 Purchase Agreement was filed with the SEC, until July 1, 2022, which is the first day of the next month following the 36-month anniversary of June 12, 2019. The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any business day (a “Regular Purchase”). The amount of a Regular Purchase may be increased under certain circumstances up to 250,000 shares, provided that Lincoln Park’s committed obligation for Regular Purchases on any business day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2019 Purchase Agreement. The 2019 Purchase Agreement limits the Company’s sale of shares of Common Stock to Lincoln Park to 10,076,680 shares of Common Stock, representing 19.99% of the shares of the Common Stock outstanding on the date of the 2019 Purchase Agreement unless (i) shareholder approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln Park under the 2019 Purchase Agreement equals or exceeds the lower of (A) the closing price of the Common Stock on the Nasdaq Capital Market immediately preceding the Execution Date or (B) the average of the closing prices of the Common Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Execution Date, and it also limits the Company’s sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of the Company’s outstanding shares of Common Stock at any given time. In consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park 324,383 shares of common stock as a commitment fee and agreed to issue up to 162,191 shares pro rata, when and if, Lincoln Park purchases at the Company’s discretion the $50,000,000 aggregate commitment. During the year ended September 30, 2019, the Company issued to Lincoln Park an aggregate of 1,839,415 shares of common stock under the 2019 Purchase Agreement, including 1,500,000 shares of common stock for an aggregate purchase price of $4,634,505 and 339,415 commitment shares, inclusive of the 324,383 initial commitment shares described above. At September 30, 2019, an amount of $45,365,495 remained available under the 2019 Purchase Agreement.

Commitments

Commitments	12 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 5 Commitments a) Lease The Company has entered into an office lease agreement under which it leases office space on a month-to-month basis until March 2020. During the year ended September 30, 2019 the Company incurred office lease expense of $190,416 (2018: $151,405). b) Litigation The Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements. The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated financial statements. c) Share Purchase Warrants At September 30, 2019, the Company had outstanding warrants to purchase 350,000 shares of common stock at $4.19 until June 2021. The following table summarizes the warrant activity during the years ended September 30, 2019 and 2018: Weighted Average Number of Shares Exercise Price ($) Balance, September 30, 2017 1,609,309 2.66 Issued 350,000 4.19 Exercised (756,143 ) 2.96 Expired (524,787 ) 3.00 Balance, September 30, 2018 678,379 2.87 Exercised (8,750 ) 1.13 Expired (319,629 ) 1.46 Balance, September 30, 2019 350,000 4.19 During the year ended September 30, 2018, 350,000 options granted to a consultant to the Company were converted to 350,000 warrants with the same exercise price. During the year ended September 30, 2019, the Company issued 4,938 shares in connection with the exercise of 8,750 warrants on a cashless basis. During the year ended September 30, 2018, an aggregate of 737,393 warrants at $3.00 per share and 18,750 warrants at $1.24 per share were exercised on a cashless basis, pursuant to which the Company issued 125,748 shares of common stock. d) Stock–based Compensation Plan 2015 Stock Option Plan The maximum number of our common shares reserved for issue under the plan is 6,050,553 shares, subject to adjustment in the event of a change of the Company’s capitalization. As a result of the adoption of the 2015 Plan, no further option awards will be granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing stock option plans remain outstanding in accordance with their terms. The 2015 Plan provides that it may be administered by the board of directors, or the board of directors may delegate such responsibility to a committee. The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2015 Plan. 2019 Stock Option Plan On January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the “2019 Plan”), which provides for the grant of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, 6,000,000 additional shares of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company’s 2007 Stock Option Plan (the “2007 Plan”) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan. The 2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. A summary of the status of Company’s outstanding stock purchase options is presented below: Weighted Weighted Average Grant Number of Average Exercise Date Fair Value Aggregate intrinsic Shares Price ($) ($) value Outstanding, September 30, 2017 5,092,030 4.13 $ 5,280,544 Granted 1,730,000 2.71 2.09 Forfeited (164,280 ) 3.66 Exercised (150,833 ) 1.18 Outstanding, September 30, 2018 6,506,917 3.83 $ 2,353,088 Granted 2,265,399 2.79 2.27 Forfeited (309,383 ) 3.25 Outstanding, September 30, 2019 8,462,933 3.58 $ 4,115,032 Exercisable, September 30, 2019 5,727,963 3.85 $ 3,275,500 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company’s stock for the options that were in-the-money at September 30, 2019. The Company recognized stock-based compensation expense of $6,430,873 during the year ended September 30, 2019 (2018: $5,517,004) in connection with the issuance and vesting of stock options and warrants in exchange for services. These amounts have been included in general and administrative expenses and research and development expenses on the Company’s statement of operations as follows: 2019 2018 General and administrative $ 3,203,165 $ 2,699,557 Research and development 3,227,708 2,817,447 Total stock-based compensation $ 6,430,873 $ 5,517,004 An amount of approximately $5,097,281 in stock-based compensation is expected to be recorded over the remaining term of such options through 2022. The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions: 2019 2018 Risk-free interest rate 2.50 % 2.73 % Expected life of options (years) 6.05 5.60 Annualized volatility 104.45 % 106.45 % Dividend rate 0.00 % 0.00 % The fair value of stock compensation charges recognized during the years ended September 30, 2019 and 2018 was determined with reference to the quoted market price of the Company’s shares on the grant date.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 6 Income Taxes The Company’s U.S. and foreign loss before income taxes are set forth below: 2019 2018 United States (18,031,016 ) (14,681,272 ) Foreign (8,181,782 ) (2,498,718 ) Total (26,212,798 ) (17,179,990 ) US Tax Reform On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act (“Tax Reform Act”). The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a territorial tax system and imposing a transition tax on deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued its ending net deferred tax liabilities at December 31, 2017. The Company did not need to recognize any provisional tax expense for the year ended September 30, 2018. The Tax Reform Act also provided for a one-time deemed mandatory repatriation of post – 1986 undistributed foreign subsidiary earnings and profits (“E&P”) as well as Global Intangible Low-Taxed Income (“GILTI”) and Base-Erosion Anti-Abuse provisions. The Company had no adjustments related to these latter noted provisions at September 30, 2018. The components of net deferred income tax assets as of September 30, 2019 and 2018 are as follows: 2019 2018 Net operating loss carryforwards $ 18,704,000 $ 13,556,000 Research and development tax credit carryforwards 1,162,000 1,605,000 Stock-based compensation 6,570,000 4 ,677,000 Unpaid charges 69,000 91,000 Intangible asset costs 30,000 35,000 Foreign exchange and other 15,000 16,000 Valuation allowance deferred tax assets (26,551,000 ) (19,981,000 ) Net deferred tax assets $ - $ - Certain deferred income tax assets in the table above as of September 30, 2018 have been adjusted to reflect state operating loss carryforwards and tax rates with a corresponding offset in the valuation allowance of approximately $3.9 million. A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements for the years ended September 30, 2019 and 2018 is as follows: 2019 2018 Income benefit at statutory federal rate $ (5,505,000 ) $ (4,215,000 ) Foreign income taxed at other rates (825,000 ) (173,000 ) Other permanent differences 140,000 131,000 Research and development credit benefit 914,000 (102,000 ) Adjustment and true up to prior years' tax provision 194,000 (82,000 ) Effect of changes in tax rates - 6,832,000 State minimum and excise taxes 82,181 72,746 Change in federal valuation allowance 5,082,000 (2,391,000 ) Income tax expense $ 82,181 $ 72,746 As of September 30, 2019, the Company had U.S. federal net operating loss carryforwards of approximately $60.8 million (2018: $50.6 million) which will begin to expire in 2027 and state net operating loss carryforwards of approximately $64.0 million which will begin to expire in 2036. In addition, the Company had approximately $3.5 million (Approximately AUD$ 5.2 million) (2018: $1.0 million) net operating loss carryforwards in Australia, which have an indefinite life and approximately $3.6 million (Approximately € 3.3 million) (2018: $0.6 million) in Germany, available to offset future taxable income in those jurisdictions. The Company evaluates its valuation allowance requirements based on projected future operations. When circumstances change, and this causes a change in management’s judgment about the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income. Because management of the Company does not currently believe that it is more likely than not that the Company will receive the benefit of these assets, a valuation allowance equal to the deferred tax asset has been established at September 30, 2019 and 2018. Uncertain Tax Positions The Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company’s tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2012. Certain of the Company’s net operating loss carryforwards in the United States may be subject to limitations by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation reduces the Company’s ability to utilize net operating loss carryforwards, under certain circumstances. The Company completed a Section 382 analysis through the fiscal year ended September 30, 2019 and currently does not believe Section 382 will apply to limit the utilization of these tax losses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Use of Estimates	a) Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimate s and the actual results, future results of operations will be affected.
Principles of Consolidation	b) Principles of Consolidation These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated.
Cash and equivalents	c) Cash and equivalents The Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months from the date of purchase to be cash equivalents.
Research and Development Expenses	d) Research and Development Expenses Research and development costs are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and stock based compensation expense, contract services including external research and development expenses incurred under arrangements with third parties such as contract research organizations (“CROs”), facilities costs, overhead costs and other related expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved. Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (“ASC”) 730, Research and Development, as these materials have no alternative future use outside of their intended use. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial or similar conditions. The objective of our policy is to match the recording of expenses in our financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical study or trial contract. In addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability of success and length of time to develop commercial applications of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties, the acquisition of patents and trademarks does not meet the definition of an asset and thus are expensed as incurred within general and administrative expenses.
Research and Development Incentive Income	e) Research and Development Incentive Income The Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit (“NYC Biotech credit”), and the Australian research and development tax incentive credit (the “Australia R&D credit”) through a program administered through the Australian Tax Office (the “ATO”), which provides for a cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company’s wholly owned subsidiary, Anavex Australia Pty Ltd. (“Anavex Australia”). The cash refund is available to eligible companies with annual aggregate revenue of less than $20.0 million (Australian) during the reimbursable period. The tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes, since the incentives are not linked to the Company’s taxable income and can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions. With respect to the Australia R&D credit, Anavex Australia may be eligible to receive the cash refund for certain research and development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by the Australian authority pursuant to an advanced overseas finding application. The Company accrues for the amount of cash refund it expects to receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval from the Department of Industry, Innovation and Science in Australia, pursuant to an approved advanced overseas finding application. The Company recognizes the amount of cash refund it expects to receive related to the NYC Biotech credit and Australian research and development tax incentive program when there is reasonable assurance that the cash refund will be received, when the relevant expenditures have been incurred, and when the amount can be reliability measured. This amount is included in Incentive and tax receivables in the accompanying consolidated balance sheets. In addition, Anavex Australia incurs Goods and Services Tax (“GST”) on services provided by Australian vendors. As an Australian entity, Anavex Australia is entitled to a refund of the GST paid. The Company’s estimate of the amount of cash refund it expects to receive related to GST incurred is included in “Incentive and tax receivables” in the accompanying consolidated balance sheets.
Basic and Diluted Loss per Share	f) Basic and Diluted Loss per Share Basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into shares of common stock that were outstanding during the period. As of September 30, 2019, loss per share excludes 8,812,933 (2018 – 7,185,296) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.
Financial Instruments	g) Financial Instruments The carrying value of the Company’s financial instruments, consisting of cash and equivalents, incentive and tax receivables, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.
Foreign Currency Translation	h) Foreign Currency Translation The functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income in the period in which they occur. The Company has determined that the functional currency of Anavex Australia Pty Limited is the US dollar. The Company has determined that the functional currency of Anavex Germany GmbH is the US dollar. The functional currency of Anavex Canada Ltd. is the Canadian dollar.
Segment and Geographic Reporting	i) Segment and Geographic Reporting Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one operating segment, which is the business of developing novel therapies for the management of CNS diseases.
Grant Income	j) Grant Income Research and development incentive income is recognized when the research and development activities have been undertaken and the Company has completed its assessment of whether such activities meet the relevant qualifying criteria. The Company recognizes such income at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants received from government and other agencies in advance of the specific research and development costs to which they relate are deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research and development costs are incurred.
Income Taxes	k) Income Taxes The Company has adopted the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes, (“ASC 740”) which requires the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.
Stock-based Compensation	l) Stock-based Compensation The Company accounts for all stock-based payments and awards under the fair value method. Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of stock-based payments to non-employees that are fully vested and non-forfeitable at the grant date are measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. The Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital. The Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in these assumptions can materially affect the fair value estimates.
Fair Value Measurements	m) Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. The book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of those instruments. At September 30, 2019 and 2018, the Company did not have any Level 3 assets or liabilities.
Recent Accounting Pronouncements	n) Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In May 2014, the FASB and the International Accounting Standards Board (IASB) issued a converged standard on revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard superseded nearly all existing revenue recognition guidance. ASU 2014-09 is effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard did not have a material impact for any period presented. In May 2017, the FASB issued ASU No. 2017-09, “Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting,” clarifying when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The new guidance was effective for the Company on a prospective basis beginning on October 1, 2018. The adoption of this standard did not have a material impact for any period presented. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance is effective for the Company beginning on October 1, 2019. The new guidance is required to be applied retrospectively with the cumulative effect recognized at the date of initial application. The Company is currently evaluating the impact this guidance will have on its financial condition, results of operations and cash flows. Other than noted above, the Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Business Description and Basi_2

Business Description and Basis of Presentation (Tables)	12 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The consolidated financial statements for the year ended September 30, 2018 presented herein have been adjusted to include an increase in net income and incentives and taxes receivable as noted below. As Previously Reported Adjustment As Adjusted Balance Sheet: Incentive and tax receivables $ 40,171 $ 1,830,186 $ 1,870,357 Total current assets $ 24,222,607 $ 1,830,186 $ 26,052,793 Total assets $ 24,376,136 $ 1,830,186 $ 26,206,322 Accumulated deficit $ (108,931,967 ) $ 1,830,186 $ (107,101,781 ) Total Stockholders' Equity $ 20,491,510 $ 1,830,186 $ 22,321,696 Total Liabilities and Stockholders' Equity $ 24,376,136 $ 1,830,186 $ 26,206,322 Statement of Operations: Research and development incentive income $ 1,629,513 $ 200,673 $ 1,830,186 Total other income, net $ 1,952,928 $ 200,673 $ 2,153,601 Net loss before provision for income taxes $ (17,380,663 ) $ 200,673 $ (17,179,990 ) Net loss and comprehensive loss $ (17,453,409 ) $ 200,673 $ (17,252,736 ) Statement of Cash Flows: Net loss $ (17,453,409 ) $ 200,673 $ (17,252,736 ) Incentive and tax receivables $ (30,423 ) $ (200,673 ) $ (231,096 )

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of share purchase warrants	The following table summarizes the warrant activity during the years ended September 30, 2019 and 2018: Weighted Average Number of Shares Exercise Price ($) Balance, September 30, 2017 1,609,309 2.66 Issued 350,000 4.19 Exercised (756,143 ) 2.96 Expired (524,787 ) 3.00 Balance, September 30, 2018 678,379 2.87 Exercised (8,750 ) 1.13 Expired (319,629 ) 1.46 Balance, September 30, 2019 350,000 4.19
Schedule of outstanding stock purchase options	A summary of the status of Company’s outstanding stock purchase options is presented below: Weighted Weighted Average Grant Number of Average Exercise Date Fair Value Aggregate intrinsic Shares Price ($) ($) value Outstanding, September 30, 2017 5,092,030 4.13 $ 5,280,544 Granted 1,730,000 2.71 2.09 Forfeited (164,280 ) 3.66 Exercised (150,833 ) 1.18 Outstanding, September 30, 2018 6,506,917 3.83 $ 2,353,088 Granted 2,265,399 2.79 2.27 Forfeited (309,383 ) 3.25 Outstanding, September 30, 2019 8,462,933 3.58 $ 4,115,032 Exercisable, September 30, 2019 5,727,963 3.85 $ 3,275,500
Schedule of statement of operations	These amounts have been included in general and administrative expenses and research and development expenses on the Company’s statement of operations as follows: 2019 2018 General and administrative $ 3,203,165 $ 2,699,557 Research and development 3,227,708 2,817,447 Total stock-based compensation $ 6,430,873 $ 5,517,004
Schedule of weighted average assumptions	The fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following weighted average assumptions: 2019 2018 Risk-free interest rate 2.50 % 2.73 % Expected life of options (years) 6.05 5.60 Annualized volatility 104.45 % 106.45 % Dividend rate 0.00 % 0.00 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The Company’s U.S. and foreign loss before income taxes are set forth below: 2019 2018 United States (18,031,016 ) (14,681,272 ) Foreign (8,181,782 ) (2,498,718 ) Total (26,212,798 ) (17,179,990 )
Schedule of deferred tax assets and liabilities	The components of net deferred income tax assets as of September 30, 2019 and 2018 are as follows: 2019 2018 Net operating loss carryforwards $ 18,704,000 $ 13,556,000 Research and development tax credit carryforwards 1,162,000 1,605,000 Stock-based compensation 6,570,000 4 ,677,000 Unpaid charges 69,000 91,000 Intangible asset costs 30,000 35,000 Foreign exchange and other 15,000 16,000 Valuation allowance deferred tax assets (26,551,000 ) (19,981,000 ) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements for the years ended September 30, 2019 and 2018 is as follows: 2019 2018 Income benefit at statutory federal rate $ (5,505,000 ) $ (4,215,000 ) Foreign income taxed at other rates (825,000 ) (173,000 ) Other permanent differences 140,000 131,000 Research and development credit benefit 914,000 (102,000 ) Adjustment and true up to prior years' tax provision 194,000 (82,000 ) Effect of changes in tax rates - 6,832,000 State minimum and excise taxes 82,181 72,746 Change in federal valuation allowance 5,082,000 (2,391,000 ) Income tax expense $ 82,181 $ 72,746

Business Description and Basi_3

Business Description and Basis of Presentation (Details) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Oct. 02, 2017	Sep. 30, 2017
Incentive and tax receivables		$ 1,870,357
Total current assets	$ 25,329,373	26,052,793
Total assets	25,329,373	26,206,322
Accumulated deficit	(133,396,760)	(107,101,781)	$ (89,849,045)
Total Stockholders' Equity	20,289,699	22,321,696		$ 25,883,508
Total Liabilities and Stockholders' Equity	25,329,373	26,206,322
Research and development incentive income	2,465,691	1,830,186
Total other income, net		2,153,601
Net loss before provision for income taxes	(26,212,798)	(17,179,990)
Net loss and comprehensive loss	(26,294,979)	(17,252,736)
Net loss	$ (26,294,979)	(17,252,736)
Incentive and tax receivables		(231,096)
As Previously Reported [Member]
Incentive and tax receivables		40,171
Total current assets		24,222,607
Total assets		24,376,136
Accumulated deficit		(108,931,967)	(91,478,558)
Total Stockholders' Equity		20,491,510
Total Liabilities and Stockholders' Equity		24,376,136
Research and development incentive income		1,629,513
Total other income, net		1,952,928
Net loss before provision for income taxes		(17,380,663)
Net loss and comprehensive loss		(17,453,409)
Net loss		(17,453,409)
Incentive and tax receivables		(30,423)
Adjustment [Member]
Incentive and tax receivables		1,830,186
Total current assets		1,830,186
Total assets		1,830,186
Accumulated deficit		1,830,186	$ 1,629,513
Total Stockholders' Equity		1,830,186
Total Liabilities and Stockholders' Equity		1,830,186
Research and development incentive income		200,673
Total other income, net		200,673
Net loss before provision for income taxes		200,673
Net loss and comprehensive loss		200,673
Net loss		200,673
Incentive and tax receivables		$ (200,673)

Business Description and Basi_4

Business Description and Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Oct. 02, 2017
Accumulated deficit				$ (133,396,760)	$ (107,101,781)	$ (89,849,045)
Decrease in net loss	$ (552,335)	$ (510,990)	$ (413,682)
As Previously Reported [Member]
Accumulated deficit					(108,931,967)	(91,478,558)
Adjustment [Member]
Accumulated deficit					$ 1,830,186	$ 1,629,513

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - shares	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Accounting Policies [Abstract]
Loss per share for potentially dilutive common shares	8,812,933	7,185,296

Other Income (Details Narrative

Other Income (Details Narrative)	12 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019AUD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2018AUD ($)	Sep. 30, 2017USD ($)
Grant income	$ 298,943		$ 149,055
Research and development incentive income	2,465,691		1,830,186
Clinical Study Grant [Member]
Awarded grant funding amount					$ 597,886
ATO R&D Credit [Member]
Research and development incentive income	2,215,691		1,647,219
ATO R&D Credit Australian Government[Member]
Research and development incentive income		$ 3,281,300		$ 2,344,486
NYC Biotech Credit [Member]
Research and development incentive income	$ 250,000		$ 182,967

Equity Offering Agreements (Det

Equity Offering Agreements (Details Narrative) - USD ($)	Jun. 07, 2019	Jul. 06, 2018	Oct. 21, 2015	Sep. 30, 2019	Sep. 30, 2018
Gross sale proceeds				$ 17,832,109	$ 8,173,920
2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Total number of shares obligated to purchase	$ 50,000,000
Agreement term	36 months
Description of purchases price	The Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase. The amount of a purchase may be increased under certain circumstances provided, however that Lincoln Park’s committed obligation under any single purchase shall not exceed $2,000,000. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the time of sales as described in the 2019 Purchase Agreement.
Number of share issued	324,383			1,839,415
Pro rata basic number of shares obligated to purchase	162,191
Number of shares issued for aggregate purchase price				1,500,000
Number of shares issued for aggregate purchase price, value				$ 4,634,505
Number of shares issued for commitment				339,415
Amount of shares remain available				$ 45,365,495
Initial commitment shares				324,383
2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member]
Number of share issued				10,076,680
Percentage of gross proceeds from sales				19.99%
Equity Offering Sales Agreement [Member] | Cantor Fitzgerald & Co [Member]
Gross sale proceeds		$ 50,000,000
Percentage of gross proceeds from sales				3.00%
Legal and accounting fees				$ 151,133
2015 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Total number of shares obligated to purchase			$ 50,000,000
Agreement term			36 months
Number of share issued				4,872,696	2,398,261
Number of shares issued for aggregate purchase price				4,848,995	2,383,580
Number of shares issued for aggregate purchase price, value				$ 13,197,604	$ 8,173,290
Number of shares issued for commitment				23,701	14,681

Commitments (Details)

Commitments (Details) - Purchase Warrants [Member] - $ / shares	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Balance, at beginning	678,379	1,609,309
Issued		350,000
Exercised	(8,750)	(756,143)
Expired	(319,629)	(524,787)
Balance, at end	350,000	678,379
Share based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]
Balance, at beginning	$ 2.87	$ 2.66
Issued		4.19
Exercised	1.13	2.96
Expired	1.46	3
Balance, at end	$ 4.19	$ 2.87

Commitments (Details 1)

Commitments (Details 1) - 2015 Omnibus Incentive Plan [Member] - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning	6,506,917	5,092,030
Granted	2,265,399	1,730,000
Forfeited	(309,383)	(164,280)
Exercised		(150,833)
Outstanding at ending	8,462,933	6,506,917
Exercisable at ending	5,727,963
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning	$ 3.83	$ 4.13
Granted	2.79	2.71
Forfeited	3.25	3.66
Exercised		1.18
Outstanding at ending	3.58	3.83
Exercisable at ending	3.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Grant Date Fair Value [Roll Forward]
Granted	$ 2.27	$ 2.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate intrinsic value [Roll Forward]
Outstanding at beginning	$ 2,353,088	$ 5,280,544
Outstanding at ending	4,115,032	$ 2,353,088
Exercisable at ending	$ 3,275,500

Commitments (Details 2)

Commitments (Details 2) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Total share based compensation	$ 6,430,873	$ 5,517,004
General and administrative [Member]
Total share based compensation	3,203,165	2,699,557
Research and development [Member]
Total share based compensation	$ 3,227,708	$ 2,817,447

Commitments (Details 3)

Commitments (Details 3)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Risk-free interest rate	2.50%	2.73%
Expected life of options (years)	6 years 18 days	5 years 7 months 6 days
Annualized volatility	104.45%	106.45%
Dividend rate	0.00%	0.00%

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Shares issued pursuant to cashless exercise of warrants	4,938
Stock issued pursuant to cashless exercise of warrants	8,750
Remaining stock based compensation	$ 5,097,281
Share based compensation	$ 6,430,873	$ 5,517,004
2015 Omnibus Incentive Plan [Member]
Maximum number of common shares reserved for future issuance	6,050,553
Description of grant option	The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date.
Expiration period	10 years
2019 Omnibus Incentive Plan [Member]
Additional shares of common stock available for issuance	6,000,000
Description of grant option	The exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s shares of common stock on the grant date.
Expiration period	10 years
General and administrative [Member]
Rent expense	$ 190,416	151,405
Share based compensation	$ 3,203,165	$ 2,699,557
Number of options granted to consultants		350,000
Number of options converted to warrants		350,000
Purchase Warrants [Member]
Warrants outstanding	350,000
Stock price	$ 4.19
Expiration date		Jul. 5, 2018
Number of share purchase warrants exercised		$ 737,393
Exercised price (in dollars per share)		$ 3
Number of share purchase warrants exercised		18,750
Exercised price (in dollars per share)		$ 1.24
Number of common stock to be issued		125,748

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
United States	$ (18,031,016)	$ (14,681,272)
Foreign	(8,181,782)	(2,498,718)
Total	$ (26,212,798)	$ (17,179,990)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 18,704,000	$ 13,556,000
Research and development tax credit carryforwards	1,162,000	1,605,000
Stock-based compensation	6,570,000	4,677,000
Unpaid charges	69,000	91,000
Intangible asset costs	30,000	35,000
Foreign exchange and other	15,000	16,000
Valuation allowance for deferred tax assets	(26,551,000)	(19,981,000)
Net deferred tax assets

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income benefit at statutory federal rate	$ (5,505,000)	$ (4,215,000)
Foreign income taxed at other rates	(825,000)	(173,000)
Other permanent differences	140,000	131,000
Research and development credit benefit	914,000	(102,000)
Adjustment and true up to prior years' tax provision	194,000	(82,000)
Effect of changes in tax rates		6,832,000
State minimum and excise taxes	82,181	72,746
Change in Federal valuation allowance	5,082,000	(2,391,000)
Income tax expense	$ 82,181	$ 72,746

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
U.S. federal net operating loss carryforwards	$ 60,800,000	$ 50,600,000
State net operating loss carryforwards	$ 64,000,000
Operating loss carry-forwards, expiration year	2027
Previous corporate income tax rate	35.00%
Revised corporate income tax rate	21.00%
Valuation allowance	$ 3,900,000
Australia [Member]
Operating loss carry-forwards	3,500,000	1,000,000
Australia [Member] | Australia, Dollars
Operating loss carry-forwards	5,200,000
Germany [Member]
Operating loss carry-forwards	3,600,000	$ 600,000
Germany [Member] | Euro Member Countries, Euro
Operating loss carry-forwards	$ 3,300,000